ESMO 2024 Summary: Key Trial Updates on IO and Targeted Treatments in GU Cancers
By
COR2ED The Heart of Medical Education
FEATURING
Ray Manneh Kopp
By
COR2ED The Heart of Medical Education
FEATURING
Ray Manneh Kopp
Dr Ray Manneh Kopp shares his views on the latest data on GU cancers presented at the ESMO 2024 congress.
Watch as he reveals what he considers to be the key clinical takeaways from the following GU cancer trials:
- NIAGARA
- EORTC-GUCG 1333/PEACE-3
- TiNivio-2
COR2ED brings together a selection of top experts across many tumour types, presenting their thoughts and insights on the most recent data to emerge from ESMO. Visit our other ESMO 2024 conference update videos here: https://cor2ed.com/n-connect/programmes/esmo-2024-lung-hcc-gi-breast-gu/?media=5
Subscribe to the COR2ED channel above to be the first to see our new Independent Medical Education programmes as they are released.
Follow GU CONNECT on social media:
X
LinkedIn
Published September 2024
The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This video is supported by COR2ED.
This video was developed by cor2ed.com
Watch as he reveals what he considers to be the key clinical takeaways from the following GU cancer trials:
- NIAGARA
- EORTC-GUCG 1333/PEACE-3
- TiNivio-2
COR2ED brings together a selection of top experts across many tumour types, presenting their thoughts and insights on the most recent data to emerge from ESMO. Visit our other ESMO 2024 conference update videos here: https://cor2ed.com/n-connect/programmes/esmo-2024-lung-hcc-gi-breast-gu/?media=5
Subscribe to the COR2ED channel above to be the first to see our new Independent Medical Education programmes as they are released.
Follow GU CONNECT on social media:
X
Published September 2024
The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This video is supported by COR2ED.
This video was developed by cor2ed.com
Comments 0
Login to view comments.
Click here to Login
